Showing results (81-90 of 223) with videos related to

Sort By:
Pageof 23
Cell Communication and Signaling : CCS|January 12, 2024
The immune checkpoint TIGIT/CD155 promotes the exhaustion of CD8 + T cells in TNBC through glucose metabolic reprogramming mediated by PI3K/AKT/mTOR signalingMingyao Huang, Xiaoqin Yu, Qing Wang, et al.
Frontiers in Medicine|September 19, 2024
Risk factors for regional lymph node metastasis in rectal neuroendocrine tumors: a population-based studyRuizhen Li, Xiaofen Li, Yan Wang, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|December 31, 2013
Calcium channel blocker verapamil accelerates gambogic acid-induced cytotoxicity via enhancing proteasome inhibition and ROS generationNingning Liu, Hongbiao Huang, Shouting Liu, et al.
Frontiers in Pharmacology|August 29, 2022
Case report: Long-term partial response of apatinib plus paclitaxel as second-line therapy in a patient with metastatic gastric cancerShengya Fu, Linjuan Li, Xiaofen Li, et al.
Frontiers in Psychology|July 17, 2024
Current status and needs of in-service training for psychiatric nurses in 24 provinces of China: a cross-sectional surveyXiaolin Tan, Minghao Pan, Zhiying Wan, et al.
Frontiers in Pharmacology|July 1, 2024
Case report: Remarkable response to later-line surufatinib in an adult patient with liver metastatic of pancreatoblastomaQingqing Leng, Wanrui Lv, Heqi Yang, et al.
Cell Communication and Signaling : CCS|October 5, 2017
CLCA1 suppresses colorectal cancer aggressiveness via inhibition of the Wnt/beta-catenin signaling pathwayXiaofen Li, Wangxiong Hu, Jiaojiao Zhou, et al.
Medicine|May 27, 2016
Surgical Intervention Improves Survival for Metastatic Non-Small Cell Lung Cancer PatientsHong Shen, Ying Cao, Xiaofen Li, et al.
Journal of Biomolecular Structure & Dynamics|December 18, 2024
Revealing therapeutic targets and drugs from Chinese medicine for ulcerative colitis using bioinformaticsFeng Xu, Xiaofen Li, Xiangpei Wang, et al.
Translational Cancer Research|February 4, 2022
Optimum adjuvant trastuzumab duration for human epidermal growth factor receptor-2 positive breast cancer: a network meta-analysis of randomized trialsJi Ma, Xiaofang Tang, Qiancheng Hu, et al.
Pageof 23